(Q37994305)

26 August 2017

title

Biomarkers of heart transplant rejection: the good, the bad, and the ugly! (English)

1 reference

26 August 2017

0 references

Carlos A Labarrere

1

1 reference

26 August 2017

Beate R Jaeger

series ordinal

2

1 reference

26 August 2017

language of work or name

1 reference

14 February 2012

1 reference

26 August 2017

published in

Translational Research

1 reference

26 August 2017

volume

159

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

238-251

1 reference

The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Gene expression profiling and cardiac allograft rejection monitoring: Is IMAGE just a mirage?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

What is the best biomarker for diagnosis of rejection in heart transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Surrogate markers of rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The use of Doppler tissue imaging to predict cellular and antibody-mediated rejection in pediatric heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Diagnostic performance of multisequential cardiac magnetic resonance imaging in acute cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Noninvasive rejection monitoring of cardiac transplants using high resolution intramyocardial electrograms: initial US multicenter experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Computerized heart allograft-recipient monitoring: a multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Complement activation products in plasma after heart transplantation in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Coagulation markers predicting cardiac transplant rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Increased expression of the lymphocyte early activation marker CD69 in peripheral blood correlates with histologic evidence of cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Urinary thromboxane B2 in cardiac transplant patients as a screening method of rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Increased serum nitrate concentration in cardiac transplant patients. A marker for acute allograft cellular rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Inability of serum myocyte death markers to predict acute cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Diagnostic efficiency of rejection monitoring after heart transplantation with cardiac troponin T is improved in specific patient subgroups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Serum matrix metalloprotease-1 and vascular endothelial growth factor--a predict cardiac allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Detection of cardiac allograft rejection and myocyte necrosis by monoclonal antibody to cardiac myosin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Annexin-V imaging for noninvasive detection of cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Anything but a biopsy: noninvasive monitoring for cardiac allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Gene-expression profiling for rejection surveillance after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiac allograft vasculopathy: current knowledge and future direction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiac allograft vasculopathy. Association with cell-mediated but not humoral alloimmunity to donor-specific vascular endothelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

De novo production of antibodies after heart or lung transplantation should be regarded as an early warning system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Early Prediction of Cardiac Allograft Vasculopathy and Heart Transplant Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Increased tissue factor expression predicts development of cardiac allograft vasculopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Vascular antithrombin and clinical outcome in heart transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Assessment of cardiac allograft vasculopathy late after heart transplantation: when is coronary angiography necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Endothelial activation and development of coronary artery disease in transplanted human hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Allograft vasculopathy versus atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant ???atheroma???

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

C-Reactive protein and cardiac allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Relationship Among Epicardial Coronary Disease, Tissue Myocardial Perfusion, and Survival in Heart Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Acute antibody-mediated rejection of cardiac transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The changing pattern of humoral rejection in cardiac transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Contemporary concepts in noncellular rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Report from a consensus conference on the sensitized patient awaiting heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Report from a consensus conference on antibody-mediated rejection in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Controversies in defining cardiac antibody-mediated rejection: need for updated criteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiac transplantation across a positive prospective lymphocyte cross-match in sensitized recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Relationship of OKT3 sensitization and vascular rejection in cardiac transplant patients receiving OKT3 rejection prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Antibody testing for cardiac antibody-mediated rejection: which panel correlates best with cardiovascular death?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

C4D immunostaining in surveillance endomyocardial biopsies from well-functioning heart allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Can C4d Immunostaining on Endomyocardial Biopsies Be Considered a Prognostic Biomarker in Heart Transplant Recipients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Deposition of C4d and C3d in cardiac transplants: A factor in the development of coronary artery vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Late Onset Antibody-Mediated Rejection and Endothelial Localization of Vascular Endothelial Growth Factor Are Associated With Development of Cardiac Allograft Vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Humoral rejection in pediatric orthotopic heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Capillary deposition of the complement fragment C4d in cardiac allograft biopsies is associated with allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Arteritis in cardiac rejection after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Utility of routine immunofluorescence staining for C4d in cardiac transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Immunohistochemistry staining of C4d to diagnose antibody-mediated rejection in cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

National conference to assess antibody-mediated rejection in solid organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status (2005-2011).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Current and future challenges in therapy for antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Antibody-mediated rejection: emergence of animal models to answer clinical questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Summary of FDA antibody-mediated rejection workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Chronic cardiac transplant arteriopathy in mice: relationship of alloantibody, C4d deposition and neointimal fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Antibody-mediated organ-allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Statins as a newly recognized type of immunomodulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The fibrin-derived peptide Bbeta(15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

The fibrin-derived peptide Bbeta15-42 is cardioprotective in a pig model of myocardial ischemia-reperfusion injury.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Systemic inflammatory response in cardiac allograft vasculopathy: high-sensitive C-reactive protein is associated with progressive luminal obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

Reliability of tissue Doppler wall motion monitoring after heart transplantation for replacement of invasive routine screenings by optimally timed cardiac biopsies and catheterizations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2012.01.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRSL.2012.01.018

1 reference

26 August 2017

1 reference